Blood Cancer Technology Expands to Immunological Reset in Autoimmune Diseases

Chimeric antigen receptor T-cell (CAR-T) therapies are being developed to deeply eliminate pathogenic B cells in systemic lupus erythematosus (SLE), lupus nephritis (LN), myasthenia gravis (MG), and systemic sclerosis (SSc), thereby reconstituting the immune system. These therapies target CD19-positive B cells or B-cell maturation antigen (BCMA)-positive plasma cells, aiming for long-term drug-free remission instead of repeated immunosuppression. This is a one-time cell therapy strategy, distinct from the CD20 inhibition of Rituxan/rituximab, the BAFF inhibition of Benlysta/belimumab, and the FcRn inhibition of Vyvgart/efgartigimod alfa.

CD19 Leaders Expand Indications and Clinical Scale

Cabaletta Bio (CABA)'s investigational resecabtagene autoleucel (rese-cel), a fully human CD19-binding CAR-T cell therapy, is in Phase 1/2 and Phase 2b development for SLE, LN, myositis, SSc, and MG. The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for SLE and LN, and Fast Track designation for MG, while the EMA granted Priority Medicine (PRIME) designation for myositis in September 2025. Kyverna Therapeutics (KYTX)'s investigational mivocabtagene autoleucel (miv-cel, KYV-101), also a fully human CD19 CAR-T cell therapy, is in Phase 2 trials for MG, multiple sclerosis, and stiff-person syndrome, and Phase 1/2 trials for LN and SSc. Expanding indications increases platform versatility, but requires separate demonstration of efficacy and safety in each disease, which also increases development costs.

Major Pharmaceutical Companies and Differentiated Platforms Follow

Novartis (NVS)'s investigational rapcabtagene autoleucel (YTB323), a rapidly manufactured CD19 CAR-T cell therapy, is enrolling 179 patients in a Phase 2 trial for SLE and LN, and 96 patients in a Phase 2 trial for SSc, with the latter directly comparing it to Rituxan. Bristol Myers Squibb (BMY)'s investigational BMS-986353 (CC-97540), a CD19-targeting NEX-T CAR-T cell therapy, is in Phase 1 trials for SLE, SSc, myositis, and rheumatoid arthritis, and a 2025 analysis showed that 94% of patients who could be evaluated remained in remission without chronic immunosuppression. Cartesian Therapeutics (RNAC)'s investigational Descartes-08, a BCMA-targeting autologous mRNA CAR-T cell therapy that is not permanently integrated into the genome, has entered Phase 3 AURORA for MG, putting it ahead in development. Miltenyi Biomedicine's MB-CART19.1, Lyell Immunopharma (LYEL)'s CD19/CD20 dual-targeting MPT-514, and Shenzhen Geno-Immune Medical Institute's 4SCAR program are also competing in Phase 1/2 trials.

Commercial Value Depends on Durability and Delivery Costs

As of August 5, 2026, CAR-T therapies for autoimmune diseases are all in development and have no history of FDA, EMA, or PMDA approval or AdComm votes. The global market for autoimmune disease therapies in 2025 is projected at $144.1 billion, with a forecast of $170.1 billion in 2032, representing a compound annual growth rate of 2.4%. Competitors include Rituxan, Benlysta, Vyvgart, and C5 inhibition with Ultomiris/ravulizumab, as well as BCMA bispecific antibodies such as teclistamab. To enable insurance coverage and widespread adoption, it is necessary to demonstrate more than two years of drug-free remission to offset the risks of CRS, ICANS, and infection, as well as the need for lymphodepleting preconditioning, customized manufacturing time, and cost.